HIV Prevention Clinical Trial
Official title:
Assessing the Effect of Contraception and the Menstrual Cycle on Pharmacokinetics, Pharmacodynamics, and Vaginal Safety in Tenofovir Vaginal Gel Users
The purpose of the study is to examine the effects of two contraceptive methods and the menstrual cycle on the pharmacokinetics, pharmacodynamics of tenofovir 1% gel and the effect of the contraceptive methods on markers of mucosal safety.
Each woman will be seen in 6 visits and will be contacted by two scheduled follow-up
telephone calls/visits. Volunteers will be consented at Visit 1 and undergo procedures to
assess whether they are eligible to continue in the study. At Visit 2 (cycle days 20-25),
after it has been confirmed that the participant meets all of the inclusion criteria and
none of the exclusion criteria, genital samples will be taken and she will be given 2
applicators of tenofovir 1% gel to insert two hours apart. She will be instructed to return
for Visit 3, approximately 3 or 11 hours after insertion of the second gel, as determined by
randomization. The participant will retain this sampling assignment throughout the study.
At Visit 3 (cycle days 20-25), blood and genital samples will be collected. The participant
will again be given 2 applicators of tenofovir 1% gel to insert two hours apart. She will be
instructed to return approximately 3 or 11 hours after insertion of the second gel for Visit
4 (cycle days 5-10) and blood and genital samples will be taken. The participant will then
start the contraceptive method that she has chosen from the two methods being evaluated in
the study.
Each participant will be contacted about 4-5 weeks after Visit 4 to confirm the next visit
date (Visit 5).
Visit 5 will take place about 6 weeks after starting contraception and will not have an
associated gel use. Follow-up genital samples will be collected at Visit 5. The participant
will be given 2 applicators of tenofovir 1% gel to insert two hours apart prior to Visit 6.
Visit 6 will take place about 10 weeks after starting contraception. Follow-up blood and
genital samples will be collected approximately 3 or 11 hours after insertion of the second
gel.
Each participant also will have a follow-up call or visit approximately 1-2 weeks after
Visit 6 to confirm that there have been no adverse experiences. If necessary, she may be
seen in an unscheduled visit for follow-up. She will then be exited from the study.
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03411577 -
Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program
|
N/A | |
Active, not recruiting |
NCT03112369 -
Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use
|
N/A | |
Not yet recruiting |
NCT03642314 -
HIV Self-testing in Implementation PrEP Study
|
N/A | |
Completed |
NCT01810315 -
Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity
|
Phase 1 | |
Completed |
NCT00984971 -
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet
|
Phase 1 | |
Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
Active, not recruiting |
NCT03255915 -
PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)
|
Early Phase 1 | |
Completed |
NCT05037513 -
Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky
|
N/A | |
Recruiting |
NCT05087680 -
An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South
|
N/A | |
Recruiting |
NCT05804461 -
Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico
|
N/A | |
Completed |
NCT03148171 -
Project WERK (Wellness Encouragement Respect Kinship)
|
N/A | |
Completed |
NCT04791007 -
OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults
|
Early Phase 1 | |
Recruiting |
NCT05412433 -
Clinic-based HIV Identification and Prevention Project Using Electronic Resources
|
N/A | |
Active, not recruiting |
NCT03977181 -
The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms
|
N/A | |
Recruiting |
NCT05165745 -
Stick2PrEP Cisgender Women and Trans Individuals
|
N/A | |
Completed |
NCT03719053 -
Single Dose Truvada Study
|
Phase 1 | |
Recruiting |
NCT03856580 -
Long-acting Biomedical HIV Prevention in Transgender Women
|
N/A | |
Completed |
NCT02750540 -
Optimization of a Tenofovir Enema for HIV Prevention
|
Phase 1 | |
Completed |
NCT01386294 -
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
|
Phase 3 | |
Completed |
NCT00993811 -
The Shang Ring: A Novel Male Circumcision Device for HIV Prevention
|
Phase 1 |